Figure 1. Main page of The Health Canada Clinical Information on Drugs and Medical Devices
Figure 2. Access clinical information packages that have been released either through drug search (circle) or from the list (box).
Figure 3. Search results for remdesivir

<table>
<thead>
<tr>
<th>Submission control number</th>
<th>Brand name</th>
<th>Manufacturer</th>
<th>Ingredients</th>
<th>Health Canada regulatory activity</th>
<th>Health Canada regulatory decision</th>
<th>Health Canada public release date</th>
</tr>
</thead>
<tbody>
<tr>
<td>246028</td>
<td>VEMLURY</td>
<td>GILEAD SCIENCES CANADA INC</td>
<td>REMDESIVIR</td>
<td>SNDB-0</td>
<td>NOC</td>
<td>2022-01-24</td>
</tr>
<tr>
<td>246001</td>
<td>VEMLURY</td>
<td>GILEAD SCIENCES CANADA INC</td>
<td>REMDESIVIR</td>
<td>NOS-NAS</td>
<td>NOC</td>
<td>2020-07-27</td>
</tr>
</tbody>
</table>
Available information for VEKLURY - Submission control number 240551

From Health Canada

Content and search results on this site are in the language provided by the manufacturer. Access and use of clinical information is governed by the Terms of Use.

Study documents

1.6.7 General Note to Reviewer
   - Annotation Report

2.6 Clinical Overview
   - Clinical Overview
   - Clinical Overview Addition

2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods
   - Summary of Biopharmaceutic Studies and Associated Analytical Methods

2.7.2 Summary of Clinical Pharmacology Studies
   - Summary of Clinical Pharmacology Studies

5.3.3.1 Plasma Protein Binding Study Reports
   - Plasma Protein Binding of GS-6734
     - Report Body
   - Plasma Protein Binding of GS-6734 as Substitute for Human OATP1B1 and OATP1B3
     - Report Body

5.3.3.2 Reports of Hepatic Metabolism and Drug Interaction Studies
   - In Vitro Inhibition Assessment of GS-6734 with Human Pgp, BCRP, OATP1B1, and OATP1B3
     - Report Body
   - In Vitro Assessment of GS-6734 as Substitute for Human OATP1B1 and OATP1B3
     - Report Body

Figure 4. Table of contents for remdesivir (submission control number 240551).

Figure 5. Link to the list of clinical information packages in progress of release

BMJ EBM
Bai I, et al. BMJ EBM 2023;0:1–7. doi: 10.1136/bmjebm-2023-112475

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s).
Figure 6. Link to the request page for clinical information packages that have yet to be released
Figure 7. Request page for clinical information packages